Genetic ablation of PKC epsilon inhibits prostate cancer development and metastasis in transgenic mouse model of prostate adenocarcinoma

Cancer Research

Volumn 71, Issue 6, 2011, Pages 2318-2327

  Hafeez, Bilal Bin ^a   Zhong, Weixiong ^a   Weichert, Jamey ^a   Dreckschmidt, Nancy E ^a   Jamal, Mohammad Sarwar ^a   Verma, Ajit K ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CCAAT ENHANCER BINDING PROTEIN BETA; CD64 ANTIGEN; CXCL9 CHEMOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOPROTEIN GP 130; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; JANUS KINASE; PROTEIN KINASE C EPSILON; STAT3 PROTEIN; TRANSCRIPTION FACTOR JUNB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL PROLIFERATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE CONTROL; GENE DELETION; HETEROZYGOSITY; HISTOPATHOLOGY; HOMOZYGOSITY; IN VIVO STUDY; METASTASIS POTENTIAL; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION; TUMOR ABLATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION;

ADENOCARCINOMA; ANIMALS; C-REACTIVE PROTEIN; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOBLOTTING; JANUS KINASES; MALE; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN KINASE C-EPSILON; RECEPTOR, EPIDERMAL GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79952760132     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-4170     Document Type: Article

References (27)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010;60:277-300.
2. Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 2009;16101:878-87.
3. Nishizuka Y. The protein kinase C family and lipid mediators for transmembrane signaling and cell regulation. Alcohol Clin Exp Res 2001;25Suppl ISBRA:3S-7S.
4. Newton AC. Protein kinase C: structural and spatial regulation by phosphorylation, cofactors, and macromolecular interactions. Chem Rev 2001;101:2353-64. (Pubitemid 35373023)
5. Mellor H, Parker PJ. The extended protein kinase C superfamily. Biochem J 1998;332:281-92. (Pubitemid 28271856)
6. Kazanietz MG. Eyes wide shut: protein kinase C isozymes are not the only receptors for the phorbol ester tumor promoters. Mol Carcinog 2000;28:5-11. (Pubitemid 30252922)
7. Denning MF. Epidermal keratinocytes: regulation of multiple cell phenotypes by multiple protein kinase C isoforms. Int J Biochem Cell Biol 2004;36:1141-6. (Pubitemid 38515654)
8. Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene 1993;8:2095-104. (Pubitemid 23226942)
9. Kazanietz MG, editor. Protein Kinase C in Cancer Signaling and Therapy. New York: Springer; 2010.
10. Wu D, Foreman TL, Gregory CW. Protein kinase C epsilon has the potential to advance the recurrence of human prostate cancer. Cancer Res 2002;62:2423-9. (Pubitemid 34411727)
11. Meshki J, Caino MC, von Burstin VA, Griner E, Kazanietz MG. Regulation of prostate cancer cell survival by protein kinase Cepsilon involves bad phosphorylation and modulation of the TNFalpha/JNK pathway. J Biol Chem 2010;285:26033-40.
12. Wu D, Thakore CU, Wescott GG, McCubrey JA, Terrian DM. Integrin signaling links protein kinase Cepsilon to the protein kinase B/Akt survival pathway in recurrent prostate cancer cells. Oncogene 2004;23:8659-72. (Pubitemid 39576473)
13. McJilton MA, Van Sikes C, Wescott GG. Protein kinase Cepsilon interacts with Bax and promotes survival of human prostate cancer cells. Oncogene 2003;22:7958-68. (Pubitemid 37175861)
14. Aziz MH, Manoharan HT, Church DR, Dreckschmidt NE, Zhong W, Oberley TD, et al. Protein kinase C epsilon interacts with signal transducers and activators of transcription 3 (Stat3), phosphorylates Stat3Ser727, and regulates its constitutive activation in prostate cancer. Cancer Res 2007;67:8828-38. (Pubitemid 47437459)
15. Aziz MH, Dreckschmidt NE, Verma AK. Plumbagin, a medicinal plant-derived naphthoquinone, is a novel inhibitor of the growth and invasion of hormone-refractory prostate cancer. Cancer Res 2008;68:9024-32.
16. Pinchuk AN, Rampy MA, Longino MA, Skinner RW, Gross MD, Weichert JP, et al. Synthesis and structure activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogs. J Med Chem 2006;49:2155-65.
17. Abdulghani J, Gu L, Dagvadorj A, Lutz J, Leiby B, Bonuccelli G, et al. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 2008;172:1717-28. (Pubitemid 351793362)
18. Chan KS, Sano S, Kiguchi K, Anders J, Komazawa N, Takeda J, et al. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J Clin Invest 2004;114:720-28. (Pubitemid 39578762)
19. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA. Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 2005;65:5054-62. (Pubitemid 40827313)
20. Huang HF, Murphy TF, Shu P, Barton AB, Barton BE. Stable expression of constitutively-activated STAT3 in benign prostatic epithelial cells changes their phenotype to that resembling malignant cells. Mol Cancer 2005;12:4-12.
21. Shukla S, MacLennan GT, Marengo SR, Resnick NI, Gupta S. Constitutive activation of PI3K-Akt and NF-kappa B during prostate cancer progression in autochthonous transgenic mouse model. Prostate 2005;64:224-39. (Pubitemid 40980864)
22. Greenberg NM, DeMayo F, Finegold MJ, Medina D, Tilley WD, Aspinall JO, et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci U S A 1995;92:3439-43.
23. Aziz MH, Hafeez BB, Sand JM, Pierce DB, Aziz SW, Dreckschmidt NE, et al. Protein kinase C epsilon mediates Stat3Ser727 phosphorylation, Stat3-regulated gene expression, and cell invasion in various human cancer cell lines through integration with MAPK cascade (RAF-1, MEK1/2, and ERK1/2). Oncogene 2010;29:3100-9.
24. Aziz MH, Manoharan HT, Sand JM, Verma AK. Protein kinase Cepsilon interacts with Stat3 and regulates its activation that is essential for the development of skin cancer. Mol Carcinog 2007;46:646-53. (Pubitemid 47255182)
25. Drachenberg DE, Elgamal AA, Rowbotham R, Peterson M, Murphy GP. Circulating levels of IL-6 in patients with hormone refractory prostate cancer. Prostate 1999;41:127-33. (Pubitemid 29446967)
26. Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT, Thompson TC. Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. J Urol 1999;161:182-7. (Pubitemid 29422316)
27. Zhong W, Peng J, He H, Wu D, Han Z, Bi X, et al. Ki-67 and PCNA expression in prostate cancer and benign prostatic hyperplasia. Clin Invest Med 2008;31:8-15.